Bristol Myers Squibb enhances clinical research and productivity with AI-powered document review
Bristol Myers Squibb (BMS), a leading pharmaceutical company, implemented an internal generative AI solution using Azure OpenAI Service on Microsoft Azure to address the company's intensive document review and research challenges. Led by Chief Digital & Technology Officer Greg Meyers, BMS developed an internal ChatGPT-powered platform tailored for clinical trial documentation, narrative generation, and computational pharmacology. The system enabled tens of thousands of documents to be queried quickly and accurately, transforming long manual review processes into near real-time insights. Generative AI was also used to convert tabular clinical trial data into text narratives, with human oversight ensuring data reliability. Additionally, BMS deployed the solution internally to maintain data privacy and avoid risks associated with public LLMs, leveraging secure agreements with Microsoft Azure. The AI-driven processes extended into protein sequence research, drug discovery, and code debugging, improving insight generation and developer productivity across the organization. BMS established strong AI governance frameworks, responsible AI guidelines, and collaborative communities (AI Collective) to ensure responsible use, bias checks, and regulatory compliance. The initiative created a secure environment for company-wide experimentation, boosting both speed and efficiency in pharma research and operations.
- Organization
- Bristol Myers Squibb
- Industry
- Pharma
- Location
- United States
- Published
- September 2023
Why do we believe this deployment?Customer identity, provider attribution, maturity, and source checks
- Customer
- Bristol Myers Squibb
- Provider
- Microsoft
- Maturity
- Production
- Linked source
- Forbes
Additionally, BMS deployed the solution internally to maintain data privacy and avoid risks associated with public LLMs, leveraging secure agreements with Microsoft Azure
Primary read
Use case focus
Showing 3 of 4
- 1AI-Driven Document Review for Clinical Trials
- 2Automated Narrative Generation from Clinical Data
- 3Accelerated Computational Pharmacology Research
- Implemented an internal ChatGPT-powered platform on Microsoft Azure using Azure OpenAI Service.
- Enabled staff to query tens of thousands of documents instantly with secure, enterprise data controls.
- Automated narrative generation from tabular clinical data with human-in-the-loop verification.
- Built responsible AI practices and an AI Collective for cross-team collaboration and governance.
- Secured data by limiting access to internal LLMs, protecting sensitive research information and ensuring compliance.
Architecture
Bristol Myers Squibb built an internal instance of ChatGPT using Azure OpenAI Service on Microsoft Azure. Employees query tens of thousands of internal documents and clinical data through secured LLM APIs running in a private Azure environment. Outputs include rapid search results, automatic narrative generation from structured clinical data, and AI-assisted programmatic support, all underpinned by AI governance and compliance measures. The system keeps a human in the loop and restricts access to ensure privacy for sensitive medical data.
Sources & evidence1
- Customer explicitly identified
- Deployment status explicitly supported
- Technical implementation details available
The same organization appears in newer AI deployment evidence.
- Same organization re-documented as recently as 2024.
Measures whether this deployment's public evidence persists — not whether the system is still in production.
AI-generated summary. Verify important details with the linked sources before relying on this case.
Explore related AI use cases
Was this useful?
Community
Comments
No published comments yet.